Early Alzheimer’s Detection: Digital Tests
- A new study in the Journal of Alzheimer's disease reveals that digital cognitive assessments can identify subtle, early indicators of cognitive impairment, potentially years before conventional methods.
- The study, titled "Precision neurocognition: An emerging diagnostic paradigm leveraging digital cognitive assessment technology," was co-authored by Dr.
- The core finding centers on how a brief, seven-minute speech-based digital cognitive assessment from Linus Health captures quantifiable data related to neurodegenerative disease risk.
Uncover groundbreaking research: Digital cognitive assessments are transforming how we approach early Alzheimer’s detection. This study highlights that analyzing response times, or latency, offers crucial insights into neurodegenerative disease risk, even before symptoms appear. Explore how these innovative methods of cognitive assessment are pivotal for identifying subtle indicators of cognitive impairment with a speech-based digital test. Researchers introduce digital biomarkers based on latency, which can identify the risk of mild cognitive impairment (MCI) and other forms of dementia. News Directory 3 brings you the latest in this groundbreaking field. Further studies promise more personalized interventions. Discover what’s next in the fight against Alzheimer’s.
Digital Cognitive Assessments Detect Early Alzheimer’s Risk
Updated June 30, 2025
A new study in the Journal of Alzheimer’s disease reveals that digital cognitive assessments can identify subtle, early indicators of cognitive impairment, potentially years before conventional methods. The research emphasizes that analyzing response times, or ”latency,” provides crucial insights into neurodegenerative disease risk, including Alzheimer’s and other dementias. This innovative approach to cognitive assessment offers a new avenue for early detection and intervention.
The study, titled “Precision neurocognition: An emerging diagnostic paradigm leveraging digital cognitive assessment technology,” was co-authored by Dr. David J.Libon, a professor at the New Jersey Institute for Prosperous Aging at Rowan University, and Dr.Rod Swenson,a clinical professor of psychiatry and behavioral science at the University of North Dakota School of Medicine and health Sciences. Both are advisors to linus Health, a company focused on digital brain health solutions. Thier work highlights the importance of early Alzheimer’s detection.
The core finding centers on how a brief, seven-minute speech-based digital cognitive assessment from Linus Health captures quantifiable data related to neurodegenerative disease risk. The assessment focuses not just on weather a patient answers correctly, but on how quickly they respond. This focus on speed and accuracy is vital for assessing cognitive impairment.
Libon and Swenson introduce digital biomarkers based on latency-the subtle pauses and reaction times when responding to questions. They demonstrate that even when answers are correct, changes in response time can be powerful biomarkers for identifying the risk of mild cognitive impairment (MCI), Alzheimer’s disease, and other forms of dementia.
“As our review demonstrates, just because an individual answers a question on a digital assessment 100% correctly does not mean a 0% risk of cognitive impairment,” said Libon. “we have shown here that the time it takes to correctly respond or recruit the necessary brain regions or strategies for efficient correct responding likely provides rich information regarding the probability of the eventual emergence of serious cognitive decline.”
This new approach is rooted in the Boston Process Approach (BPA), a neuropsychological assessment framework pioneered by Dr. Edith Kaplan. The BPA focuses on deriving cognitive function insights from a participant’s process of completing cognitive tasks, rather than simply their final answer. This understanding allows Linus Health’s digital solution to uncover critical insights that traditional methods might miss.
What’s next
further research will focus on refining thes digital biomarkers and expanding their application to diverse populations, potentially leading to more personalized and effective interventions for those at risk of cognitive decline.